Healthy Dialogue

CRISPR genome editing is a revolutionary technology that can be used to make highly targeted changes in DNA in living cells. JAMA Associate Editor W. Gregory Feero, MD, PhD, Maine Dartmouth Family Medicine Residency, and Matthew J. Kan, MD, PhD, University of California San Francisco, discuss how CRISPR works and how CRISPR-based technologies are being used in ongoing trials to treat a wide variety of medical conditions. Related Content:

• Treatment of Genetic Diseases With CRISPR Genome Editing
• With First CRISPR Trials, Gene Editing Moves Toward the Clinic

Interview with Michael D. Cabana, MD, MA, MPH, USPSTF member and coauthor of Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS.

Related Content:

• Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents
• Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents
• Screening for Type 2 Diabetes in Children and Adolescents

Over a nearly 40-year career at the head of the National Institute of Allergy and Infectious Diseases, Anthony Fauci, MD, has seen a seismic shift in the way that science is communicated to and received by the public. In conversation with JAMA Network Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, Fauci reflects on his career at NIAID, the joys and challenges of advising 7 presidents, and shares his strategies for communicating scientific information in an ever-changing environment. Related Content:

• Dr Fauci and the Art of Science Communication
• Dr Anthony Fauci—Communicating Science in a Polarized Era

Interview with John B. Wong, MD, USPSTF member and coauthor of Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS. Related Content:

• Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
• Statin Use for the Primary Prevention of Cardiovascular Disease in Adults
• Statins for the Prevention of Cardiovascular Disease
• Statin Usage in Primary Prevention—Comparing the USPSTF Recommendations With the AHA/ACC/Multisociety Guidelines
• Statins for Primary Cardiovascular Disease Prevention
• Statins and Primary Atherosclerotic Cardiovascular Disease Prevention—What We Know, Where We Need to Go, and Why Are We Not There Already?

President Biden has signed into law the Inflation Reduction Act containing important provisions related to prescription drug costs. JAMA Health Forum Editor John Z. Ayanian, MD, MPP, and Deputy Editor Melinda B. Buntin, PhD, discuss the effects of these provisions on patients with Aaron S. Kesselheim, MD, JD, MPH, of Harvard Medical School and Brigham and Women's Hospital.

Related Content:

• New Reforms to Prescription Drug Pricing in the US
• Estimating Rebates and Other Discounts Received by Medicare Part D
• Estimation of the Share of Net Expenditures on Insulin Captured by US Manufacturers, Wholesalers, Pharmacy Benefit Managers, Pharmacies, and Health Plans From 2014 to 2018
• Spending by the Centers for Medicare & Medicaid Services Before and After Confirmation of Benefit for Drugs Granted US Food and Drug Administration Accelerated Approval, 2012 to 2017
• Improving Prescription Drug Affordability Through Regulatory Action

In this Author Interview, JAMA Deputy Editor Gregory Curfman, MD, discusses the state of coronary artery bypass surgery in 2022 with E. Magnus Ohman, MD, from Duke University. The conversation emphasizes methods to preserve patency of saphenous vein bypass grafts, the subject of an article in the August 9, 2022, issue of JAMA. Dr Ohman wrote the accompanying Editorial. Related Content:

• Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery
• Balancing the Risks and Benefits of Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery

Electronic health records (EHRs) hold great promise to assist clinicians, but current versions are less user-friendly than ideal. JAMA Associate Editor Tracy Lieu, MD, MPH, spoke with Kevin B. Johnson, MD, MS, University of Pennsylvania, and William W. Stead, MD, Vanderbilt University Medical Center, about how to improve EHRs to protect cognitive attention and optimize their potential to provide cognitive support to health care professionals.

Related Content:

• Making Electronic Health Records Both SAFER and SMARTER

On August 3, 2022, the US Department of Health and Human Services released 2 major reports in response to a presidential memo calling for a whole-of-government response to the SARS-CoV-2 sequelae known as "Long COVID." JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, discusses these new reports and the research and support needed to address this pervasive health concern with HHS Assistant Secretary for Health Rachel Levine, MD. Recorded July 29, 2022.

Related Content:

• Addressing the Long-term Effects of COVID-19
• Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers
• Long COVID: The US Federal Response (Video)

Interview with Lori Pbert, PhD, USPSTF member and coauthor of Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors: US Preventive Services Task Force Recommendation Statement. Hosted by JAMA Senior Editor Kristin L. Walter, MD, MS.

Related Content:

• Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Known Cardiovascular Disease Risk Factors
• Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Disease Risk Factors
• Behavioral Counseling Interventions to Promote a Healthy Diet and Physical Activity to Prevent CVD in Adults Without Risk Factors
• Implications of the New Recommendation on Behavioral Counseling Interventions to Promote Healthy Eating and Physical Activity
• Improving Behavioral Counseling for Primary Cardiovascular Disease Prevention
• Updated USPSTF Recommendations for Behavioral Counseling Interventions

Exercise limitation is a cardinal manifestation of heart failure with reduced ejection fraction (HFrEF), but it is not consistently improved by any of the current guideline-directed medical therapies. JAMA Deputy Editor Gregory Curfman, MD, discusses whether omecamtiv mecarbil can improve peak exercise capacity in patients with HFrEF with Gregory D. Lewis, MD, from Massachusetts General Hospital, and Mark H. Drazner, MD, MSc, from University of Texas Southwestern Medical Center.

Related Content:

• Effect of Omecamtiv Mecarbil on Exercise Capacity in Chronic Heart Failure With Reduced Ejection Fraction: The METEORIC-HF Randomized Clinical Trial
• Omecamtiv Mecarbil as a Therapy for Heart Failure With Low Ejection Fraction